Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Ensure your covered population has access to Wegovy Undeniably powerful weight loss in both the pill and pen 1-3 Proven weight-loss efficacy in both pen and pill formats for adults with obesity or overweight with at least one weight-related comorbidity, in addition to diet and exercise Major cardiovascular event risk reduction that matters The only GLP-1 RA indicated for weight loss proven to help prevent life-threatening CV events for adults with established CVD and either overweight or obesity, along with diet and exercise 1,4,5 More ways to start than ever before Available in a once-daily pill or once-weekly pen , with broad access options for your commercially insured population and the lowest Wegovy self-pay offer yet 6 Explore the study information under Efficacy & Safety CV, cardiovascular
Feng, X., Sureda, A., Jafari, S., Memariani, Z., Tewari, D., Annunziata, G., Barrea, L., Hassan, T
The 12 mg dose in TRIUMPH-4 led to a 28.7% loss over 68 weeks, while tirzepatide in the SURMOUNT-1 trial produced approximately 22.5% loss over 72 weeks
Disarmed versions: retain supportive or educational content but remove the active, efficacy-driving components (e.g., CBT exercises, feedback loops)
That's lower than the 7.1% discontinuation rate seen with semaglutide 2.4 mg in the STEP trials, suggesting tirzepatide is better tolerated at maximum doses despite the higher absolute milligram amount
US$ 21.76
US$ 22.53
US$ 29.72
US$ 27.11
